Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer

被引：51

作者：

Wallin, Jeffrey J. ^{[1
]}

Guan, Jane ^{[1
]}

Prior, Wei Wei ^{[1
]}

Edgar, Kyle A. ^{[1
]}

Kassees, Robert ^{[1
]}

Sampath, Deepak ^{[1
]}

Belvin, Marcia ^{[1
]}

Friedman, Lori S. ^{[1
]}

机构：

[1] Genentech Inc, Canc Signaling, San Francisco, CA 94080 USA

来源：

SCIENCE TRANSLATIONAL MEDICINE | 2010年 / 2卷 / 48期

关键词：

CELL-CYCLE PROGRESSION; AKT/PROTEIN KINASE-B; 3-KINASE INHIBITION; GLIOBLASTOMA CELLS; MAMMALIAN TARGET; PIK3CA MUTATIONS; DNA-PKCS; PHOSPHORYLATION; ACTIVATION; RESISTANCE;

D O I：

10.1126/scitranslmed.3000630

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway is frequently disrupted in cancer and implicated in multiple aspects of tumor growth and survival. In addition, increased activity of this pathway in cancer is associated with resistance to chemotherapeutic agents. Therefore, it has been hypothesized that PI3K inhibitors could help to overcome resistance to chemotherapies. We used preclinical cancer models to determine the effects of combining the DNA-damaging drug doxorubicin with GDC-0941, a class I PI3K inhibitor that is currently being tested in early-stage clinical trials. We found that PI3K inhibition significantly increased apoptosis and enhanced the antitumor effects of doxorubicin in a defined set of breast and ovarian cancer models. Doxorubicin treatment caused an increase in the amount of nuclear phospho-Akt(Ser473) in cancer cells that rely on the PI3K pathway for survival. This increased phospho-Akt(Ser473) response to doxorubicin correlates with the strength of GDC-0941's effect to augment doxorubicin action. These studies predict that clinical use of combination therapies with GDC-0941 in addition to DNA-damaging agents will be effective in tumors that rely on the PI3K pathway for survival.

引用

页数：8

共 45 条

[1] Mechanism of activation of protein kinase B by insulin and IGF-1 [J].

Alessi, DR ;

Andjelkovic, M ;

Caudwell, B ;

Cron, P ;

Morrice, N ;

Cohen, P ;

Hemmings, BA .

EMBO JOURNAL, 1996, 15 (23) :6541-6551

[2] Oncogenic PI3K deregulates transcription and translation [J].

Bader, AG ;

Kang, SY ;

Zhao, L ;

Vogt, PK .

NATURE REVIEWS CANCER, 2005, 5 (12) :921-929

[3] PKBα/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival [J].

Bozulic, Lana ;

Surucu, Banu ;

Hynx, Debby ;

Hemmings, Brian A. .

MOLECULAR CELL, 2008, 30 (02) :203-213

[4]

Brognard J, 2001, CANCER RES, V61, P3986

[5] Cell death by mitotic catastrophe: a molecular definition [J].

Castedo, M ;

Perfettini, JL ;

Roumie, T ;

Andreau, K ;

Medema, R ;

Kroemer, G .

ONCOGENE, 2004, 23 (16) :2825-2837

[6] QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].

CHOU, TC ;

TALALAY, P .

ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55

[7] Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies [J].

Chou, Ting-Chao .

PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :621-681

[8]

Clark AS, 2002, MOL CANCER THER, V1, P707

[9] Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage [J].

Falck, J ;

Coates, J ;

Jackson, SP .

NATURE, 2005, 434 (7033) :605-611

[10] The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer [J].

Folkes, Adrian J. ;

Ahmadi, Khatereh ;

Alderton, Wendy K. ;

Alix, Sonia ;

Baker, Stewart J. ;

Box, Gary ;

Chuckowree, Irina S. ;

Clarke, Paul A. ;

Depledge, Paul ;

Eccles, Suzanne A. ;

Friedman, Lori S. ;

Hayes, Angela ;

Hancox, Timothy C. ;

Kugendradas, Arumugam ;

Lensun, Letitia ;

Moore, Pauline ;

Olivero, Alan G. ;

Pang, Jodie ;

Patel, Sonal ;

Pergl-Wilson, Giles H. ;

Raynaud, Florence I. ;

Robson, Anthony ;

Saghir, Nahid ;

Salphati, Laurent ;

Sohal, Sukhjit ;

Ultsch, Mark H. ;

Valenti, Melanie ;

Wallweber, Heidi J. A. ;

Wan, Nan Chi ;

Wiesmann, Christian ;

Workman, Paul ;

Zhyvoloup, Alexander ;

Zvelebil, Marketa J. ;

Shuttleworth, Stephen J. .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (18) :5522-5532

← 1 2 3 4 5 →